A Phase Ib/IIa study of the BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) Meeting Abstract
| Authors: | Aggarwal, R.; Abida, W.; Schweizer, M.; Pantuck, A.; Nanus, D.; Heath, E.; Lakhotia, S.; Hansen, H.; Silverman, M.; Bauman, L.; Snyder, M.; Campeau, E.; Norek, K.; Attwell, S.; O'Farrell, M.; Smith, S.; Wegge, P.; Jahagirdar, R.; Alumkal, J. |
| Abstract Title: | A Phase Ib/IIa study of the BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) |
| Meeting Title: | 110th Annual Meeting of the American Association for Cancer Research (AACR) |
| Journal Title: | Cancer Research |
| Volume: | 79 |
| Issue: | 13 Suppl. |
| Meeting Dates: | 2019 Mar 29-Apr 3 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2019-07-01 |
| Language: | English |
| ACCESSION: | WOS:000488129900085 |
| DOI: | 10.1158/1538-7445.Am2019-ct095 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: CT095 -- Source: Wos |
